PURPOSE: To evaluate the clinical pharmacology of exogenous alkaline phosphatase (AP). METHODS: Randomized, double-blind, placebo-controlled sequential protocols of (1) ascending doses and infusion duration (volunteers) and (2) fixed dose and duration (patients) were conducted at clinical pharmacology and intensive care units. A total of 103 subjects (67 male volunteers and 36 patients with severe sepsis) were administered exogenous, 10-min IV infusions (three ascending doses) or 24-72 h continuous (132.5-200 U kg(-1) 24 h(-1)) IV infusion with/without preceding loading dose and experimental endotoxemia for evaluations of pharmacokinetics, pharmacodynamics, safety parameters, antigenicity, inflammatory markers, and outcomes. RESULTS: Linearity and dose-proportionality were shown during 10-min infusions. The relatively short elimination half-life necessitated a loading dose to achieve stable enzyme levels. Pharmacokinetic parameters in volunteers and patients were similar. Innate immunity response was not significantly influenced by AP, while renal function significantly improved in sepsis patients. CONCLUSIONS: The pharmacokinetics of exogenous AP is linear, dose-proportional, exhibit a short half-life, and are not influenced by renal impairment or dialysis.
RCT Entities:
PURPOSE: To evaluate the clinical pharmacology of exogenous alkaline phosphatase (AP). METHODS: Randomized, double-blind, placebo-controlled sequential protocols of (1) ascending doses and infusion duration (volunteers) and (2) fixed dose and duration (patients) were conducted at clinical pharmacology and intensive care units. A total of 103 subjects (67 male volunteers and 36 patients with severe sepsis) were administered exogenous, 10-min IV infusions (three ascending doses) or 24-72 h continuous (132.5-200 U kg(-1) 24 h(-1)) IV infusion with/without preceding loading dose and experimental endotoxemia for evaluations of pharmacokinetics, pharmacodynamics, safety parameters, antigenicity, inflammatory markers, and outcomes. RESULTS: Linearity and dose-proportionality were shown during 10-min infusions. The relatively short elimination half-life necessitated a loading dose to achieve stable enzyme levels. Pharmacokinetic parameters in volunteers and patients were similar. Innate immunity response was not significantly influenced by AP, while renal function significantly improved in sepsispatients. CONCLUSIONS: The pharmacokinetics of exogenous AP is linear, dose-proportional, exhibit a short half-life, and are not influenced by renal impairment or dialysis.
Authors: Madhu S Malo; Shaluk Biswas; Mario A Abedrapo; Lisa Yeh; Alexander Chen; Richard A Hodin Journal: DNA Cell Biol Date: 2006-12 Impact factor: 3.311
Authors: Rinaldo Bellomo; Claudio Ronco; Ravindra L Mehta; Pierre Asfar; Julie Boisramé-Helms; Michael Darmon; Jean-Luc Diehl; Jacques Duranteau; Eric A J Hoste; Joannes-Boyau Olivier; Matthieu Legrand; Nicolas Lerolle; Manu L N G Malbrain; Johan Mårtensson; Heleen M Oudemans-van Straaten; Jean-Jacques Parienti; Didier Payen; Sophie Perinel; Esther Peters; Peter Pickkers; Eric Rondeau; Miet Schetz; Christophe Vinsonneau; Julia Wendon; Ling Zhang; Pierre-François Laterre Journal: Ann Intensive Care Date: 2017-05-04 Impact factor: 6.925
Authors: Peter Pickkers; Suzanne Heemskerk; Jeroen Schouten; Pierre-François Laterre; Jean-Louis Vincent; Albertus Beishuizen; Philippe G Jorens; Herbert Spapen; Michael Bulitta; Wilbert H M Peters; Johannes G van der Hoeven Journal: Crit Care Date: 2012-01-23 Impact factor: 9.097
Authors: Jesse Davidson; Suhong Tong; Amanda Hauck; D Scott Lawson; James Jaggers; Jon Kaufman; Eduardo da Cruz Journal: Crit Care Date: 2012-08-20 Impact factor: 9.097
Authors: Esther Peters; Ravindra L Mehta; Patrick T Murray; Jürgen Hummel; Michael Joannidis; John A Kellum; Jacques Arend; Peter Pickkers Journal: BMJ Open Date: 2016-09-27 Impact factor: 2.692
Authors: Esther Peters; Jules A A C Heuberger; Renger Tiessen; Andrea van Elsas; Rosalinde Masereeuw; Jacques Arend; Jasper Stevens; Peter Pickkers Journal: Clin Pharmacokinet Date: 2016-10 Impact factor: 6.447